Product Specifications:
• Component A: CJC-1295 No DAC (Tetrasubstituted GRF 1-29) | CAS: 863288-34-0
• Component B: Ipamorelin Acetate | CAS: 170851-70-4
• Combined Vial Content: 10mg total lyophilized mass (1:1 Ratio)
• Purity Level: ≥98.0% individual component purity verified via HPLC analysis
• Physical Form: Lyophilized white cake/powder
Product Overview:
This reference material blends two distinct growth hormone secretagogues into a single matrix to facilitate comparative co-administration modeling in research environments. CJC-1295 (Without Drug Affinity Complex) functions as a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). Ipamorelin behaves as a highly selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a).
When paired, these compounds allow researchers to evaluate dual-pathway signaling mechanisms. Scientists study how the GHRH pathway amplification (CJC-1295) interacts with selective growth hormone release pulses (Ipamorelin) in vitro, without altering baseline cortisol or prolactin levels.
Storage Conditions:
Store in dry, lyophilized form at -20°C for long-term preservation. Upon reconstitution using laboratory-grade diluents (such as bacteriostatic water), the solution must be stored at 2°C to 8°C and protected from intense light or physical agitation to prevent rapid peptide chain degradation.
Reviews
There are no reviews yet.